Does Insurance Cover GLP-1 Medications? [2026] Coverage Guide

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-1 receptor agonists are prescription medications with potential side effects and contraindications. Always consult a board-certified physician or endocrinologist before starting, stopping, or switching any medication. Individual results vary significantly based on medical history, dosage, and adherence.

Affiliate Disclosure: Some links in this article may be affiliate links. If you sign up through our links, The GLP-1 Daily may earn a commission at no extra cost to you. This does not influence our editorial recommendations.

---

The short version: insurance coverage for GLP-1 medications in 2026 is a mess. Some people pay $0 per month. Others pay $1,400. Same drug. The difference comes down to your plan type, your diagnosis, and how hard you're willing to fight.

Here's what changed. Major insurers — including BCBS, Cigna, Harvard Pilgrim, and UnitedHealthcare — tightened coverage criteria in January 2026, with most now limiting GLP-1 coverage to patients with Type 2 diabetes only. Meanwhile, Medicare is expanding access through a new bridge program that caps copays at around $50/month for enrollees starting mid-2026. The landscape is fractured, and knowing exactly where you stand can save you thousands.

This guide covers every insurance type, every workaround, and every cost-reduction strategy available right now.

---

The Current State of GLP-1 Insurance Coverage in 2026

The GLP-1 insurance landscape shifted dramatically between late 2025 and early 2026. Understanding where things stand right now is the first step toward figuring out your options.

The Numbers Paint a Stark Picture

According to GoodRx tracking data, the number of people with zero commercial insurance coverage for Zepbound increased from 51% to 56% in early 2026 — that translates to over 109 million Americans with no path to coverage for this medication. An additional 12 million people lost coverage compared to 2025. For Wegovy, over 41 million people now have no commercial insurance coverage at all.

Why the pullback? Employers are getting crushed by costs. A Peterson-KFF Health System Tracker study found that firms saw roughly a 30% increase in GLP-1 spending year-over-year, driven by surging utilization. Some employers responded by dropping weight-loss coverage entirely. Others added stricter requirements — higher BMI thresholds, mandatory behavioral health programs before approval, or limiting coverage to specific GLP-1 brands.

What Changed in January 2026

Several major shifts hit simultaneously:

• BCBS, Cigna, Harvard Pilgrim, and UnitedHealthcare updated their formulary guidelines, restricting GLP-1 coverage primarily to Type 2 diabetes indications
• Employer self-funded plans (which cover roughly 65% of commercially insured workers) increasingly carved out anti-obesity medications from their drug benefits
• Pharmacy benefit managers (PBMs) renegotiated rebate structures, with some dropping brand-name GLP-1s from preferred formulary tiers entirely
• Prior authorization requirements tightened across nearly every plan that still offers coverage, with additional documentation requirements including proof of failed lifestyle interventions

The result is a two-tier system. If you have a Type 2 diabetes diagnosis and a GLP-1 prescription for glucose management, coverage is generally good — most plans cover Ozempic and Mounjaro under their diabetes formularies. If you're seeking a GLP-1 for weight management only, coverage is significantly harder to secure.

For a deeper dive into the medications themselves and how they work, see our beginner's guide to GLP-1 medications.

The Diagnosis Factor

This is the single most important variable in your coverage equation. The same medication — literally the same molecule — gets different coverage treatment depending on why it's prescribed:

• Ozempic (semaglutide for Type 2 diabetes): Covered by most commercial plans with prior authorization
• Wegovy (semaglutide for weight management): Covered by fewer plans, with stricter criteria
• Mounjaro (tirzepatide for Type 2 diabetes): Generally covered, often preferred over Ozempic due to rebate agreements
• Zepbound (tirzepatide for weight management): The most restricted — 56% of commercially insured people have zero coverage

This distinction matters because Ozempic and Wegovy contain the same active ingredient (semaglutide), and Mounjaro and Zepbound contain the same active ingredient (tirzepatide). The only difference is the approved indication and dosing. For more on how these medications compare head-to-head, check our semaglutide vs tirzepatide comparison.

---

Private Insurance Coverage: What Each Plan Type Offers

Not all private insurance is created equal. Your coverage depends on the type of plan, your employer's benefit design, and the specific formulary your PBM manages.

Employer-Sponsored Plans

About 160 million Americans get their insurance through an employer. Within that group, the coverage picture splits into two categories:

Fully-insured plans (smaller employers, typically <500 employees) are governed by state insurance regulations. Some states have mandated coverage for anti-obesity medications, which means these plans must cover GLP-1s prescribed for weight management. However, the mandates don't prevent plans from imposing prior authorization, step therapy, or quantity limits.

Self-funded plans (larger employers) are governed by federal ERISA law, which means state mandates don't apply. These employers choose exactly what to cover. And increasingly, they're choosing not to cover GLP-1s for weight loss. The Peterson-KFF data shows the trend clearly: as GLP-1 costs rose 30%+ year-over-year, many self-funded employers eliminated or restricted anti-obesity medication benefits entirely.

What to look for in your plan documents:

• Check the formulary (drug list) — search for semaglutide, tirzepatide, Ozempic, Wegovy, Mounjaro, and Zepbound by both brand and generic names
• Look for exclusions — many plans explicitly list "anti-obesity medications" or "weight loss drugs" as excluded categories
• Review the prior authorization criteria — even if the drug is on formulary, your plan may require documented BMI ≥30 (or ≥27 with comorbidities), failed diet/exercise attempts, and sometimes a behavioral health evaluation
• Check the tier placement — GLP-1s on formulary may be on Tier 4 or 5 (specialty tier), meaning copays of $100-$500/month even with coverage

ACA Marketplace Plans

Individual plans purchased through Healthcare.gov or state exchanges have a mixed record on GLP-1 coverage. The ACA requires coverage of FDA-approved prescription drugs, but plans have significant flexibility in which drugs they include on their formularies and at what cost-sharing level.

In 2026, most marketplace plans:

• Cover Ozempic and Mounjaro for diabetes (required under essential health benefits)
• May or may not cover Wegovy and Zepbound for weight management
• Place GLP-1s on higher formulary tiers with substantial cost-sharing
• Require prior authorization regardless of indication

If you're shopping for a marketplace plan specifically because you want GLP-1 coverage, the only reliable approach is to check each plan's formulary before enrolling. Call the insurer directly. Get the formulary tier and estimated copay in writing. Don't rely on the summary of benefits alone — it often doesn't list specific drugs.

High-Deductible Health Plans (HDHPs) with HSAs

Here's an underappreciated strategy. If you have a high-deductible health plan with a Health Savings Account (HSA), you can use pre-tax HSA dollars to pay for GLP-1 medications — even if your plan doesn't cover them. This doesn't reduce the cash price, but it does give you a tax advantage of 22-37% depending on your marginal tax bracket.

With GLP-1 costs ranging from $149/month (Wegovy pill at lowest available price) to $1,350/month (brand-name Wegovy injection without discounts), the HSA tax savings can be meaningful:

• At a 24% marginal tax rate, $1,350/month becomes an effective cost of ~$1,026/month
• Annual HSA contribution limits for 2026 are $4,300 for individuals and $8,550 for families
• If you have a Flexible Spending Account (FSA) instead of an HSA, GLP-1 medications also qualify — but FSAs have lower contribution limits and use-it-or-lose-it rules

---

Medicare Coverage: The 2026 Expansion

Medicare's approach to GLP-1 coverage changed more in the past year than in the previous decade. The shift is significant, but the details matter.

The Medicare GLP-1 Bridge Program

In a landmark policy move, CMS (the Centers for Medicare & Medicaid Services) announced the Medicare GLP-1 Bridge program, designed to provide affordable access to GLP-1 medications for Medicare enrollees. Key details:

• Eligible medications: Injectable Mounjaro, Ozempic, Wegovy, Zepbound, and the Wegovy pill
• Copay structure: Approximately $50/month after any deductibles for enrollees with stand-alone Part D prescription plans or Medicare Advantage plans with drug coverage
• Rollout timeline: Mid-2026, with phased implementation
• Eligibility: Medicare beneficiaries with qualifying diagnoses (Type 2 diabetes, obesity with comorbidities, or cardiovascular risk reduction based on SELECT trial data)

This is a massive change. Before this program, Medicare Part D technically covered Ozempic for diabetes but did not cover any GLP-1 specifically for weight management. The Inflation Reduction Act's $2,000 out-of-pocket cap for Part D (which took effect in 2025) already helped reduce costs for Medicare enrollees using Ozempic for diabetes. The Bridge program goes further by explicitly including weight management indications.

Traditional Medicare (Parts A and B)

Original Medicare parts A and B still do not cover outpatient prescription drugs, including GLP-1 medications. You need a Part D plan or Medicare Advantage plan with drug coverage to access any prescription drug benefit.

However, Medicare Part B does cover certain medical services related to obesity treatment, including:

• Intensive behavioral therapy (IBT) for obesity — face-to-face counseling sessions
• Diabetes self-management training (DSMT) for enrollees with diabetes
• Medical nutrition therapy (MNT) for diabetes and kidney disease

These services can complement GLP-1 therapy but don't provide the medication itself.

Medicare Advantage Plans

Medicare Advantage (Part C) plans are administered by private insurers and must cover everything Original Medicare covers, plus they often add additional benefits. In 2026, many Medicare Advantage plans include prescription drug coverage with GLP-1 formulary access.

What varies between MA plans:

• Formulary inclusion: Not all MA plans include all GLP-1 brands. Some prefer Mounjaro over Ozempic, or vice versa, based on rebate agreements with manufacturers
• Step therapy: Some plans require you to try metformin (and sometimes other diabetes drugs) before approving a GLP-1
• Quantity limits: Plans may cap the supply at a 30-day fill, preventing 90-day prescriptions that could reduce per-unit costs
• Prior authorization: Nearly universal — expect a 3-14 day processing time

If you're in the Medicare Annual Enrollment Period (October 15 – December 7), check each plan's formulary for your specific GLP-1 medication. The Medicare Plan Finder tool at medicare.gov lets you search by drug name.

---

Medicaid Coverage: State-by-State Variation

Medicaid coverage for GLP-1 medications varies dramatically by state. There is no federal mandate requiring state Medicaid programs to cover anti-obesity medications, though most cover GLP-1s when prescribed for Type 2 diabetes.

States With Broader GLP-1 Coverage

A growing number of states have expanded Medicaid formularies to include GLP-1 receptor agonists for weight management, particularly after the FDA's cardiovascular benefit approval for Wegovy. As of early 2026, states with more comprehensive coverage tend to include:

• GLP-1s for BMI ≥30 (or ≥27 with comorbidities) with prior authorization
• Preferred brands selected through supplemental rebate agreements with manufacturers
• Step therapy requirements (try lifestyle intervention first, then older medications like metformin or phentermine)
• Duration limits (initial approval for 6-12 months, then re-authorization)

States With Restrictive Coverage

Many states still limit Medicaid GLP-1 coverage to Type 2 diabetes only. In these states, Medicaid beneficiaries seeking GLP-1s for weight management face the same barriers as uninsured patients — full cash pricing or alternative discount programs.

How to Check Your State's Medicaid Formulary

1. Visit your state Medicaid program's website (search "[your state] Medicaid preferred drug list")
2. Download the current Preferred Drug List (PDL)
3. Search for semaglutide, tirzepatide, or the specific brand name
4. Note the prior authorization criteria — you'll need these details for your prescriber
5. If your medication isn't on the PDL, ask your doctor about filing an exception request

The exception request process is your best tool here. If the preferred formulary drug has failed or is contraindicated, most state Medicaid programs must provide coverage for the non-preferred alternative. Document everything. Keep records of every medication tried, every side effect experienced, every clinical outcome measured.

---

The Prior Authorization Process: A Step-by-Step Walkthrough

Prior authorization is the gatekeeper. Even when your insurance technically covers a GLP-1 medication, you'll almost certainly need to navigate this process. Here's exactly how it works and how to improve your odds of approval.

What Prior Authorization Requires

Insurance companies use prior authorization to verify that a prescribed medication is medically necessary before they agree to pay for it. For GLP-1 medications, the typical requirements include:

Clinical documentation your prescriber must submit:

• BMI measurement: Most plans require BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (Type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease)
• Lifestyle intervention history: Documentation that the patient has attempted diet and exercise modifications — some plans require 3-6 months of documented attempts
• Failed alternatives: Evidence that less expensive medications (metformin, phentermine, naltrexone-bupropion) were tried and either failed or caused intolerable side effects
• Lab work: Recent HbA1c (for diabetes indication), lipid panel, liver function tests, kidney function
• Comorbidity documentation: Diagnosed conditions that elevate the medical necessity argument — cardiovascular disease is particularly strong after the SELECT trial demonstrated semaglutide's 20% reduction in major adverse cardiovascular events

The Timeline

• Initial submission: Your prescriber's office submits the prior authorization request electronically or by fax (yes, fax is still standard)
• Review period: Insurance companies typically have 72 hours for urgent requests and up to 15 business days for standard requests
• Decision: Approved, denied, or sent back for additional information
• If denied: You have the right to appeal. First-level appeals go back to the insurer. External (independent) appeals go to a third-party reviewer

How to Maximize Approval Chances

The patients who get approved tend to do these things:

1. Work with your prescriber's office proactively. Don't assume they know what documentation to include. Print out your insurer's specific prior authorization criteria (usually available on the insurer's provider portal) and give it to your doctor's office. Make their job easier.

2. Get the diagnosis right. If you have Type 2 diabetes, the PA request should lead with the diabetes indication. If you have a BMI ≥30 and cardiovascular risk factors, the SELECT trial data supporting Wegovy for cardiovascular risk reduction is powerful documentation.

3. Document failed alternatives aggressively. Even if you only tried metformin for two weeks and had terrible GI side effects, that's a documented failed trial. Log it. Your prescriber should note the medication name, dose, duration, and specific reason for discontinuation.

4. Include supporting lab work. Recent labs showing elevated HbA1c, high triglycerides, or elevated blood pressure readings strengthen the medical necessity argument.

5. Ask about peer-to-peer review. If your PA is denied, your prescriber can request a peer-to-peer review — a phone call between your doctor and the insurance company's medical director. Denial overturn rates after peer-to-peer review are significantly higher than paper-only appeals.

For a comprehensive look at the health benefits that strengthen your medical necessity case, see our GLP-1 medications benefits guide.

The Appeal Process

Roughly 40-50% of initial GLP-1 prior authorization requests are denied. But denial is not the end of the road. The appeal process has multiple levels:

Level 1 — Internal Appeal:

• File within 30-60 days of denial (check your plan's specific deadline)
• Submit additional clinical documentation your prescriber may not have included initially
• Include peer-reviewed studies supporting the medication for your specific condition
• Success rate: approximately 30-40% of denied PAs are overturned on internal appeal

Level 2 — External Appeal:

• If the internal appeal is denied, you can request an independent external review
• A third-party physician reviews your case without affiliation to the insurer
• Federal law guarantees this right for most plan types
• Success rate: generally higher than internal appeals, though data varies by state

Level 3 — State Insurance Commissioner Complaint:

• For fully-insured plans (not self-funded ERISA plans), you can file a complaint with your state insurance commissioner
• This doesn't guarantee coverage but creates regulatory pressure on the insurer
• Particularly effective when the denial appears to violate state coverage mandates

---

What GLP-1 Medications Cost Without Insurance

When insurance isn't an option, you need to know the real numbers. Here's what GLP-1 medications actually cost out of pocket in April 2026, along with every discount pathway available.

Current Cash Prices (April 2026)

Medication	Indication	List Price/Month	Lowest Available Price/Month
Ozempic	Type 2 Diabetes	~$935	~$199 (manufacturer savings)
Wegovy (injection)	Weight Management	~$1,349	~$199 (select discount programs)
Wegovy (pill)	Weight Management	~$549	~$149 (introductory pricing)
Mounjaro	Type 2 Diabetes	~$1,023	~$199 (manufacturer savings)
Zepbound	Weight Management	~$1,059	~$299 (Eli Lilly direct)

The gap between list price and the lowest available price is enormous. That gap is where the savings programs, discount cards, and manufacturer coupons live. For a complete cost breakdown including compounded options, see our compounded vs brand-name GLP-1 guide.

Manufacturer Savings Programs

Both Novo Nordisk and Eli Lilly operate savings programs that can dramatically reduce costs for eligible patients:

Novo Nordisk (Ozempic, Wegovy):

• Savings card for commercially insured patients: may reduce copays to as low as $25/month for qualifying patients
• The card does NOT work with Medicare, Medicaid, Tricare, or other government-funded insurance
• Eligibility and specific savings amounts change frequently — check novocare.com for current terms
• Uninsured patients may qualify for patient assistance programs (PAPs) that provide the medication at no cost, though income limits apply

Eli Lilly (Mounjaro, Zepbound):

• LillyDirect program offers Zepbound at $299/month shipped directly to patients — no insurance required
• Mounjaro savings card for commercially insured patients: copay reductions available
• Income-based patient assistance for qualifying uninsured patients

Telehealth and Direct-to-Consumer Programs

A new category of GLP-1 access has emerged: telehealth platforms that bundle the prescription consultation with medication fulfillment. These programs typically offer:

• Virtual prescriber visit ($0-$99)
• Compounded or brand-name GLP-1 medication
• Monthly pricing that bundles everything
• Ongoing clinical monitoring via app or messaging

Prices from major telehealth platforms range from $149/month to $599/month depending on the medication type and whether it's compounded or brand-name. These programs can be a viable option for patients without insurance coverage, but vet the platform carefully — confirm they use licensed pharmacies and board-certified prescribers.

The Compounded GLP-1 Option

Compounded semaglutide and tirzepatide remain available through licensed 503A and 503B pharmacies at significantly lower costs — typically $150-$400/month. These are not FDA-approved finished products, but they use the same active pharmaceutical ingredient.

Important caveats:

• Not covered by any insurance plan
• Quality varies by pharmacy — look for FDA-registered 503B outsourcing facilities
• Dosing requires manual syringe preparation (no pre-filled pens)
• The FDA has increased enforcement against non-compliant compounders in 2026
• Salt form differences (semaglutide sodium vs semaglutide base) can affect dosing accuracy

This is a legitimate option for many patients but carries real tradeoffs. Read our full compounded vs brand-name comparison before going this route.

---

Cost-Reduction Strategies That Actually Work

Beyond the obvious (insurance, savings cards), there are several lesser-known strategies that can meaningfully reduce your GLP-1 costs.

1. Dose Splitting and Titration Management

Work with your prescriber on an optimized dosing schedule. Some patients achieve their treatment goals at lower maintenance doses. A 0.5mg semaglutide dose costs the same per pen as a 1.0mg dose, but the pen lasts longer at the lower dose. This isn't about cutting corners — it's about finding your minimum effective dose with your doctor's guidance.

2. Manufacturer Patient Assistance Programs

If your household income falls below certain thresholds (typically 400% of the federal poverty level, or roughly $62,400 for an individual in 2026), you may qualify for free medication through manufacturer PAPs. These programs are different from savings cards:

• Novo Nordisk PAP: Provides Ozempic and Wegovy at no cost for qualifying patients
• Eli Lilly Solutions Center: Provides Mounjaro and Zepbound for eligible patients
• Application requires income verification and proof of no insurance coverage (or coverage that doesn't include the medication)

3. International Pharmacy Options

Some patients explore international pharmacy options, particularly Canadian pharmacies. GLP-1 prices in Canada are significantly lower than US list prices — though still not cheap. Important considerations:

• The FDA technically prohibits personal importation of prescription drugs, though enforcement against individuals importing a personal supply (90-day max) has historically been minimal
• Verify the pharmacy through the Canadian International Pharmacy Association (CIPA) or PharmacyChecker
• Shipping and customs delays can disrupt your dosing schedule
• This is a gray area legally, and rules could change

4. Employer Advocacy

If your employer's plan doesn't cover GLP-1s, consider advocating for change. The business case is real: GLP-1 therapy for employees with obesity can reduce downstream costs from diabetes, cardiovascular disease, joint replacements, sleep apnea treatment, and disability claims. Some employers have responded to employee advocacy by adding obesity medication coverage, particularly when presented with cost-offset data.

5. Clinical Trial Enrollment

Active clinical trials for GLP-1 receptor agonists — including next-generation compounds like retatrutide (a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously) — provide medication at no cost to enrolled participants. Check ClinicalTrials.gov for open enrollment near your location.

Retatrutide trials are particularly noteworthy. Early data from Phase 2 trials showed weight loss of up to 24% of body weight at 48 weeks — potentially exceeding the efficacy of currently available GLP-1s. Phase 3 trials are underway, and enrollment may be available in your area.

6. Combination Approaches

Some patients reduce costs by combining a lower-dose GLP-1 with lifestyle interventions, behavioral counseling, or less expensive adjunctive medications. This can allow for a lower GLP-1 dose while maintaining results. Always discuss this with your prescriber — dose adjustments should be medically supervised, never self-directed.

---

What's Coming: Insurance Coverage Trends for Late 2026 and Beyond

The GLP-1 coverage landscape is evolving rapidly. Several developments on the horizon could reshape access and affordability.

Medicare Expansion Impact

The Medicare GLP-1 Bridge program launching mid-2026 will be the biggest single coverage expansion for GLP-1 medications in US history. With approximately 67 million Medicare beneficiaries, even partial uptake could dramatically increase GLP-1 utilization — and put pressure on manufacturers to negotiate pricing concessions to handle the volume.

The program's success (or failure) will likely influence future policy. If the Bridge program demonstrates cost savings through reduced hospitalizations for diabetes complications, cardiovascular events, and obesity-related conditions, it could build the case for broader mandated coverage across all insurance types.

Generic and Biosimilar Competition

While true generic semaglutide is not yet on the US market, the competitive pressure from compounded versions and anticipated biosimilar entries is already forcing pricing concessions. Novo Nordisk's decision to offer the Wegovy pill at a lower price point than the injection, and Eli Lilly's LillyDirect program offering Zepbound at $299/month, are direct responses to market pressure.

When biosimilar competition does arrive — likely in the 2027-2028 timeframe for semaglutide — prices should decrease substantially, which will in turn make insurance coverage more feasible for plans that currently exclude GLP-1s due to cost.

State Legislative Action

Multiple states are considering or have passed legislation addressing GLP-1 coverage:

• Parity laws: Requiring insurers to cover FDA-approved anti-obesity medications on the same terms as medications for other chronic conditions
• Step therapy reform: Limiting the number of failed alternative medications insurers can require before approving GLP-1s
• Prior authorization reform: Requiring faster turnaround times and "gold carding" for prescribers with high approval rates

These legislative efforts are driven by the growing recognition that obesity is a chronic disease, not a lifestyle choice, and that effective medications should be accessible through standard insurance benefits.

Employer Trend Reversal?

The employer pullback from GLP-1 coverage may be temporary. As more data emerges on the total cost of care impact — including reduced spending on diabetes management, cardiovascular interventions, and orthopedic procedures — forward-thinking employers may reverse course. Early real-world evidence suggests that every dollar spent on GLP-1 therapy for qualifying employees generates downstream savings in medical and disability costs over a 2-5 year horizon.

Some large employers are already piloting value-based GLP-1 programs that tie continued coverage to clinical outcomes — patients who demonstrate adherence, attend follow-up appointments, and engage in lifestyle modifications maintain coverage; those who discontinue therapy early may not be re-eligible for a specified period.

---

Frequently Asked Questions

Does my insurance cover Wegovy for weight loss?

It depends on your specific plan. As of 2026, over 41 million commercially insured Americans have no coverage for Wegovy. Check your plan's formulary and prior authorization criteria. If you have a Type 2 diabetes diagnosis, coverage is more likely (though Ozempic, the diabetes-indicated version of the same drug, would be prescribed instead). Call the member services number on your insurance card and ask specifically whether semaglutide for weight management is covered, what tier it's on, and what the prior authorization requirements are.

Can I use my HSA or FSA to pay for GLP-1 medications?

Yes. GLP-1 medications prescribed by a licensed physician are qualified medical expenses for both Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs). This applies whether or not your insurance covers the medication. Using pre-tax dollars effectively reduces your cost by your marginal tax rate — typically 22-37% for most GLP-1 patients. The 2026 HSA contribution limits are $4,300 for individuals and $8,550 for families.

What should I do if my prior authorization is denied?

Appeal. Approximately 30-40% of GLP-1 prior authorization denials are overturned on appeal. Start with an internal appeal to your insurer, including additional clinical documentation, relevant studies (such as the SELECT cardiovascular outcomes trial for Wegovy), and a letter of medical necessity from your prescriber. If the internal appeal fails, request an external independent review — a right guaranteed by federal law for most plan types. Ask your prescriber about a peer-to-peer review call with the insurer's medical director, which has higher overturn rates than paper appeals alone.

Will Medicare Part D cover my Ozempic or Mounjaro?

Medicare Part D covers Ozempic and Mounjaro when prescribed for Type 2 diabetes. The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D (effective since 2025) limits your maximum spending. For weight management indications, the new Medicare GLP-1 Bridge program launching mid-2026 will expand coverage to include Wegovy, Zepbound, and other GLP-1s with copays around $50/month after deductibles. Check medicare.gov's Plan Finder tool for your specific plan's formulary.

What's the cheapest way to get GLP-1 medications without insurance in 2026?

The lowest-cost options as of April 2026 are: the Wegovy pill at approximately $149/month through discount programs, compounded semaglutide at $150-$400/month through licensed pharmacies, and Zepbound at $299/month through Eli Lilly's LillyDirect program. Manufacturer patient assistance programs may provide medications at no cost for patients with household incomes below 400% of the federal poverty level. Telehealth platforms bundle consultations and medication starting around $149-$599/month. For income-qualifying patients, manufacturer PAPs from Novo Nordisk and Eli Lilly are the absolute cheapest option — free.

---

Related Reading

• GLP-1 Medications for Beginners: What to Know Before Your First Visit — Start here if you're new to GLP-1 therapy
• Semaglutide vs Tirzepatide: Head-to-Head Comparison [2026] — Compare the two main GLP-1 classes
• Compounded vs Brand Name GLP-1: Safety, Cost, and Legality [2026] — Deep dive into the compounded alternative
• GLP-1 Medications Benefits: What the Latest Research Shows [2026] — Clinical evidence supporting GLP-1 therapy

-- The GLP-1 Daily Team